RBC Capital Starts Eli Lilly (LLY) at Outperform

RBC Capital analyst Trung Huynh initiates coverage on Eli Lilly (NYSE: LLY) with a Outperform rating and a price target of $1,250.00.

The analyst comments "We initiate with an Outperform rating and $1,250 PT driven by obesity franchise dominance through 2030. Street sentiment is largely positive but there remains some nervousness on elevated expectations, Medicare pricing headwinds, and positioning risks as LLY reapproaches $1tr market-cap. However, we believe consensus materially undervalues transformative catalysts on the horizon that will crystallize value, including the Medicare agreement, orforglipron's ex-US potential driving $35bn+ peak sales, and multiple pipeline catalysts. LLY's structural advantages—patent exclusivity through 2035+, manufacturing lead, and 14% revenue CAGR toward $130bn by 2033—warrant multiple expansion from 31x to 37x as fundamentals override positioning concerns."

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $1058.56 yesterday.

You May Also Be Interested In